je.st
news
Tag: investigational
Results from Mercks Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet
2015-10-06 01:01:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the publication of results from C-SURFER, the first Phase 31 clinical trial to investigate an all-oral, ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in treatment-nave and treatment-experienced patients with advanced chronic kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1) infection. Language: English Contact: MerckMedia Contacts:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck KGaA, Darmstadt, Germany, And Pfizer Announce FDA Orphan Drug Designation For Investigational Immunotherapy Avelumab In Merkel Cell Carcinoma
2015-09-30 08:25:02| drugdiscoveryonline News Articles
Merck KGaA, Darmstadt, Germany, and Pfizer recently announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for the investigational cancer immunotherapy avelumab* for the treatment of Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer
Tags: germany
cell
drug
announce
Pivotal Phase 3 Studies of Bezlotoxumab, Mercks Investigational Antitoxin to Prevent Clostridium Difficile Infection Recurrence, Met Primary Endpoint
2015-09-20 18:30:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Company Plans to Submit New Drug Applications in U.S., EU and Canada in 2015 Results Presented for the First Time at ICAAC/ICC 2015 Annual Meeting KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the two pivotal Phase 3 clinical studies for bezlotoxumab, its investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence, met their primary efficacy endpoint: the reduction in C. difficile recurrence through week 12 compared to placebo, when used in conjunction with standard of care antibiotics for the treatment of C. difficile. Language: English Contact: MerckMedia Contacts:Doris Li, 908-246-5701Ian McConnell, 973-901-5722orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: met
primary
studies
prevent
Results of Phase 2 Study of Mercks Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015
2015-09-18 21:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Company Initiates Pivotal Phase 3 Studies Evaluating Relebactam in Combination with Imipenem/Cilastatin for Treatment of Serious Bacterial Infections KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the companys investigational beta-lactamase inhibitor for the treatment, in combination with imipenem/cilastatin (an approved carbapenem antibiotic), of complicated intra-abdominal infections, met its primary endpoint, and that Merck is now initiating pivotal Phase 3 studies. Language: English Contact: MerckMedia:Doris Li, (908) 246-5701Ian McConnell, (973) 901-5722orInvestor:Teri Loxam, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
study
presented
phase
Mercks Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor, Achieved Similar A1C Reductions to JANUVIA (sitagliptin) in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy
2015-09-16 16:16:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that omarigliptin, Mercks investigational once-weekly DPP-4 inhibitor in development for adults with type 2 diabetes, achieved its primary efficacy endpoint in a Phase 3 study. Omarigliptin was found to be non-inferior to Mercks once-daily DPP-4 inhibitor, JANUVIA (sitagliptin), at reducing patients A1C* levels from baseline, with similar A1C reductions achieved in both groups. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Michael Close, 310-617-1067Kristen Drake, 917-647-6223orInvestorsJustin Holko, 908-740-1879Teri Loxam, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: on
type
similar
controlled
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] next »